The physiology, pharmacology and therapeutic manipulation of the internal anal sphincter

Oliver M Jones MA FRCS1,2, Alison F Brading BSc PhD1, Neil J McC Mortensen MD FRCS2

1Department of Pharmacology, Mansfield Road and 2Department of Colorectal Surgery, John Radcliffe Hospital, Oxford, United Kingdom

Correspondence: Dr Oliver Jones, Department of Pharmacology, Mansfield Road, Oxford, United Kingdom OX1 3QT.
Telephone +00441865-271878, fax +00441865-271853, e-mail oliver.jones@pharm.ox.ac.uk
Received for publication May 22, 2001. Accepted November 28, 2001

Recent research into the physiology and pharmacology of the internal anal sphincter has elucidated the importance of this structure in health and disease. Its pharmacological manipulation for therapeutic gain has focused mainly on agents to reduce internal anal sphincter tone, a ‘chemical sphincterotomy’ that might heal chronic anal fissure. However, drugs to increase sphincter tone, and augment intermittent and appropriate relaxation are also being evaluated. The initial results with this medical approach to anorectal disease have often been disappointing, failing to match the results achievable with surgery, and many of these drugs have a high rate of side effects in the short term. However, clinical trials have yet to establish the optimum doses, dose intervals and routes of administration for many of these therapies. Furthermore, it is uncertain whether this medical approach should be applied to all patients or just to an as yet undefined subgroup. Certainly, even in the current environment of uncertainty, there is little reason not to try medical manipulation of the internal sphincter as first-line treatment. Surgery remains an option for treatment failures; patients responding to pharmacological manipulation of the internal sphincter are spared the long term risks of continence that are inherent in many surgical procedures on the anorectum.

Key Words: Anal fissure; Anal sphincter; Fecal incontinence
H2 receptor antagonists and proton pump inhibitors have approached these conditions in much the same way as the benign anorectal disease has the potential to alter the quality of life. Although still in its infancy, pharmacological therapy of attempts to modify IAS function with drug therapy.

The present review begins with a summary of the current understanding of the basic physiology and pharmacology of the IAS. This knowledge has been used as the basis for the pharmacological reduction and augmentation of anal canal pressure, and success in these areas is examined. Finally, as a glimpse into the future, the challenge of intermittent but appropriate sphincter relaxation is examined.

**PHYSIOLOGICAL CONSIDERATIONS**

Over 80 years ago, it was proposed that the IAS received an excitatory sympathetic innervation and an inhibitory parasympathetic innervation (1). Although this arrangement differs from that of most of the rest of the gastrointestinal tract, it is duplicated in other sphincters, including that of the urethra. The sympathetic input (from the thoracolumbar spinal cord) comes predominantly via the hypogastric plexus, while the parasympathetic input (S1-3) relays in the pelvic plexus.

The enteric nervous system, often described as the third division of the autonomic nervous system, is responsible for the gastrointestinal functions seen after sectioning of extrinsic nerves (2). This enteric nervous system comprises two plexi of ganglia: Auerbach’s (myenteric) plexus and Meissner’s (submucous) plexus. It is responsible for the peristaltic contractions of the gut and also mediates entire reflex pathways.

Local anesthetic blockade of the pudendal nerves demonstrates that the smooth muscle IAS is responsible for between 50% and 85% of resting anal tone (3). The striated, voluntary, external anal sphincter makes a greater contribution during periods of rectal distension. The tone of the IAS is due to both intrinsic myogenic tone and extrinsic sympathetic innervation (4,5). That there is a tonic discharge of sympathetic nerves maintaining anal canal pressure can be demonstrated by effecting sympathetic blockade by either high spinal anesthesia (6) or infusion of the alpha-adrenoceptor antagonist phentolamine (7). Both cause reductions in anal canal pressure of around 50%. The effects of presacral nerve stimulation at operation have been shown to induce both a fall and rise in anal canal pressure (8,9), probably reflecting little more than recruitment of different nerve types by varying stimulation parameters. There is probably negligible tonic parasympathetic discharge because low spinal anesthesia (L5/S1) has little effect on sphincter tone.

Superimposed on the tonic state of the IAS is an intermittent slow and ultraslow wave activity (10). Ultraslow wave activity is defined as discrete pressure fluctuations with a low frequency of around 1 to 2 cycles/min, and 10% above and below baseline resting pressure. Slow wave activity occurs at a frequency of 15 to 35 cycles/min, with an amplitude of 5 mmHg (11,12). The importance of these waves is not fully understood. They may act to counter rectal pressure waves (13) or may keep the anal canal empty and prevent desensitization of the anoderm (14). These waves are often deranged in patients with fecal incontinence (15), although it is not clear whether this is a marker of, or a contributor to, incontinence.

The rectoanal inhibitory reflex was first described by Gowers (16) in 1877. It is characterized by transient IAS relaxation in response to rectal distension, which brings the rectal contents into contact with the sensory epithelium of the anal canal, allowing discrimination of solid, liquid and gas. This process, known as anorectal sampling, is frequently abnormal in incontinent patients (17). Interestingly, this reflex is absent altogether in patients with Hirschsprung’s disease, a condition characterized morphologically by a lack of myenteric ganglia in the distal colon and rectum (18). It is present, however, following sectioning of the hypogastric nerves, suggesting that the machinery necessary for the reflex is present entirely within the bowel wall and pelvic plexus (19).

**PHARMACOLOGICAL FEATURES**

Dale (20) originally classified the autonomic nervous system on the basis of neurotransmitter type. Nerves synthesizing and releasing acetylcholine, termed ‘cholinergic nerves’, are the predominant nerves that make up preganglionic efferent fibres of both the sympathetic and parasympathetic subdivisions. Acetylcholine acts at these autonomic ganglia through nicotinic receptors. Postganglionic parasympathetic fibres are also cholinergic, although acetylcholine released at the target tissue from these nerves acts via muscarinic receptors. Postganglionic sympathetic fibres release noradrenaline.

Many of the features of the IAS have been established in vitro using techniques such as the superfusion organ bath (21). IAS smooth muscle strips generate spontaneous myogenic tone after equilibration in vitro – a feature duplicated in other sphincteric smooth muscles. This tone is dependent on extracellular calcium and its entry via L-type calcium channels (22). IAS strips relax upon addition of carbachol (an acetylcholine analogue), an effect blocked by pretreatment with atropine, a muscarinic antagonist. By contrast, noradrenaline causes a dose-dependent contraction of muscle strips. Pretreatment with the alpha-blocker phentolamine unmasks a relaxation effect of noradrenaline, which is mediated via beta-receptors. Indeed, the beta-
adrenergic agonist isoprenaline causes a relaxation in vitro. These fundamental pharmacological features of the IAS differ from the circular and longitudinal layers of the rectum, and the anal longitudinal muscle – evidence of ‘sphincter specialization’ of the IAS smooth muscle (23).

With appropriate parameters, electric field stimulation causes a relaxation of IAS strips that is blocked by tetrodotoxin, but not by atropine or guanethidine (24), confirming that the relaxation is nerve mediated, but neither cholinergic or adrenergic in nature. The search for this non-adrenergic noncholinergic transmitter led to several possibilities, including ATP (24), vasoactive intestinal peptide (25,26) and carbon monoxide (27).

O’Kelly et al (28) provided several convincing lines of evidence that nitric oxide was the most important non-adrenergic noncholinergic transmitter in the human IAS. Electric field stimulation of IAS strips was shown to cause a relaxation, which could be blocked by the addition of N-nitro-L-arginine, a nitric oxide synthase inhibitor. This inhibition was reversed by the addition of an excess of L-arginine, a nitric oxide precursor. There is also morphological evidence that nitric oxide is an important neurotransmitter in the IAS. Nitric oxide synthase-staining neurons have been demonstrated in the rectal myenteric plexus and anal canal by immunohistochemistry (29). This immunoreactivity was found to co-localize with wheat germ agglutinin conjugated to horseradish peroxidase after injection into the IAS in nerve tracer experiments (30). These findings further implied that nitric oxide might be responsible for mediating the rectoanal inhibitory reflex.

Finally, it has been shown that the relaxant effects of carbachol in vitro may be blocked not only by atropine, but also by nitric oxide synthase inhibitors (31). Similarly, it has been shown that the action of vasoactive intestinal peptide is dependent on nitric oxide synthesis (32). These nitrergic nerves presumably possess receptors for both acetylcholine and vasoactive intestinal peptide. This and other aspects of the pharmacology of the IAS are summarized in Figure 1.

PHARMACOLOGICAL MANIPULATION
Agents to decrease IAS tone
Of all aspects of clinical research of the IAS, agents to decrease IAS tone have been studied more than any others. This is because anal fissure, accounting for 10% of new outpatients in one study (33), has long been recognized to be associated with IAS spasm (34). Although this sphincter spasm may not be the cause of the acute fissure, it is probably central to the development of chronicity. The posterior commissure of the anal canal, an area that receives relatively few branches of the inferior rectal artery, is the most common site for anal fissures (35). With the level of IAS spasm seen in anal fissure, the perfusion index of the anoderm of this portion of the anal canal falls to 0.29, a level that would produce rest pain in the lower limb (36). Lateral sphincterotomy produces a fall in anal canal pressure, with an associated rise in anodermal blood flow to levels seen in controls (37). Sphincter spasm is not the only abnormality associated with anal fissure. Ultraslow waves have also been found more frequently in patients with fissures than in control subjects (38), and there is some evidence that these patients also have an abnormal rectoanal inhibitory reflex (39). The significance, if any, of these latter two observations is unknown.

Both lateral sphincterotomy and manual dilation of the anus produce fissure healing rates in excess of 90% (40). A drawback of surgery is an increased incidence of incontinence in the long term. Some centres have published surgical results combining good healing rates with negligible long term incontinence (41). Most series with long term follow-up, however, report rates of around 25% for incontinence to flatus and/or solid stool (42,43).

Nitric oxide donors
In 1990, before it was known that nitric oxide was an important neurotransmitter in this tissue, L’Hopital and co-workers (44) showed that sublingual glyceryl trinitrate (GTN) was effective in reducing IAS spasm. The first use of topical nitroglycerin to reduce anal canal pressure was by Guillemot and co-workers (45,46) in normal and constipated patients. GTN and other exogenous nitrates are broken down by cellular metabolism to yield nitric oxide and effect IAS relaxation (47). The Nottingham trial (48) was a randomized, prospective, double-blind, placebo controlled trial of 0.2% GTN paste in patients with chronic anal fissure. Eighty patients were recruited and instructed to apply the paste twice daily. Significant reductions in anal resting pressure and an increase in anodermal blood flow (measured by laser Doppler flowmetry) were observed in the treated group, but not in controls. At the end of eight weeks of treatment, healing was observed in 68% of treated patients but only 8% of controls – a finding that was highly significant. Headaches were reported by 58% of patients in the treatment arm, but by only 18% of those in the placebo group. The length of follow-up in this study was short, although a
longer term assessment of these patients and those from another trial (49) (total 44 patients) were reported separately (50). At an average of 28 months' follow-up, 11 patients were found to have recurrent symptoms. Of these patients, three opted for sphincterotomy (two of whom had failed to heal on a second course of GTN), two healed spontaneously and the remaining six all healed with a second course of GTN.

Further trials in support of these findings followed. A randomized, prospective, double-blind, placebo controlled trial of 0.2% GTN paste for the treatment of chronic fissure was published a couple of years later (51), comprising 43 patients. The design was broadly similar to that in the Nottingham study (48), although treatment was given for only four weeks. Healing was observed in 46% of those taking the active treatment, compared with 16% taking placebo, which was a significant difference. However, when eight patients with fissures after four weeks of GTN were reassessed at a mean of 28 months, five had relapsed. Bacher et al (52) reported results of a trial involving patients with acute or chronic fissures, who were randomly assigned to receive four weeks of treatment with either GTN paste or lignocaine gel. In this study comprising 35 patients, healing in the GTN treatment group was found to be 80% — significantly better than the 40% healing rates observed in the lignocaine treatment group. Healing was assessed by clinicians who were blinded to the patients' treatment. Carapeti et al (53), in a prospective, double-blind study, randomly assigned patients to three groups: placebo; 0.2% GTN three times daily; and 0.2% GTN, increasing every week by 0.1% to a maximum of 0.6%. Only patients with chronic anal fissures were included, and treatment was given for eight weeks. Considering the two treatment groups together, healing was observed in 67% of treated patients compared with 32% of control subjects — a significant difference.

However, a recent prospective, randomized, multicentre study by Altomare et al (54) failed to demonstrate any significant difference in healing between patients with chronic anal fissure treated with four weeks of 0.2% GTN and those treated with placebo. The healing rate in the treatment group was 49%, but this rate was less than the 52% healing rate observed in the placebo group. The healing rate of the group who received placebo was, therefore, more than six times that in the Nottingham trial (48), raising the obvious suggestion that the fissures themselves were substantially different. It is possible that more patients with acute fissures were included in the Italian study (54) because many of these fissures heal spontaneously. The less impressive healing rate in the group that received active treatment might be attributable to the short (four-week) treatment course used. After one month of therapy in the Nottingham trial (48), less than 20% of patients were healed.

A randomized, double-blind study compared 0%, 0.1%, 0.2% and 0.4% GTN paste applied twice or three times daily for up to eight weeks. There was no significant difference in the rate of healing; the fissure healing rate was broadly similar, around 50% in each of the eight groups, containing 304 patients in total. Pain was more significantly reduced in the group that received the 0.4% GTN paste (55).

The latter two trials, in association with the poor healing rates seen in many unrandomized studies (56,57), have tempered the initial enthusiasm engendered by GTN. Possible reasons for its lack of efficacy include its short duration of action (as little as 90 min in one study) (58), the incidence of headaches that may affect compliance (59) and tachyphylaxis (60).

Not surprisingly, two recent trials have compared GTN paste with sphincterotomy (61,62). Both showed poor healing rates in the medically treated group, contrasting with high healing rates in the surgical group. Both trials claimed to have negligible rates of incontinence in the surgical group. However, follow-up to assess incontinence was performed only at six months or less in the two studies, which cannot be considered to have proved the safety of sphincterotomy. Anal canal pressures fall with age, and the surgeon does not know what further traumas, such as obstetric injury, await the sphincter in the future. It may often be many years before the damage of surgery is evident.

Other nitric oxide donors need to be evaluated, including isosorbide dinitrate (ISDN). ISDN itself may be responsible for the short term effects this drug, although its metabolite isosorbide mononitrate may be responsible for the longer term effects of lowering anal resting pressure. There have been two reports of the efficacy of ISDN in healing anal fissure (63,64), although there is little compelling evidence that it is superior to GTN in terms of tolerability or efficacy. L-arginine was also proven to be effective at reducing mean anal resting pressure by around 40% in 10 volunteers (65). Further data are awaited.

GTN paste (0.2%) has also been evaluated as an agent to reduce pain after hemorrhoidectomy (66). In a randomized, prospective, double-blind, placebo controlled trial, patients on active treatment had less pain, measured on a visual analogue score, although the difference was not significant. However, patients had less total and daily narcotic use, a difference that attained significance after the fourth postoperative day. Headaches were reported by eight of 15 patients who received the active treatment.

Botulinum toxin
Botulinum toxin has been used for a number of indications since the report of its first clinical use for strabismus in 1980 (67). Its initial use in the treatment of anorectal disease was reported in an open-label study of 12 patients with chronic anal fissure. Each received 5 U of botulinum toxin into the external anal sphincter (68). After three months, 10 patients demonstrated healing.

In a prospective, double-blind, placebo controlled trial, 30 patients with chronic anal fissure were randomly assigned to receive either 20 U of botulinum toxin or saline injection into the IAS (69). Both groups also received laxatives. After two months, the healing rate in the treatment
group was 73%, compared with 13% in the control group—
a statistically significant difference. The resting pressure in
the treated group was significantly reduced by 25%, while
that in the placebo group was unaffected. Voluntary squeeze
pressure was unaffected in both groups.

The optimal dose of botulinum toxin in anal fissure
treatment is another unresolved area of controversy. The external anal sphincter (68), intersphincteric space (74) and IAS (73) have all been used. Certainly, injection into the IAS in the posterior midline appears to be superior to injection in the anterior midline, at least for posterior fissures (75).

Much of the inconsistency reflects uncertainty regarding
the mechanism of action of botulinum toxin. The toxin appears
to exert its effect on the IAS, reducing myogenic tone and blocking sympathetic nerves (76). Clinical trials are needed, however, to answer the separate question of where the site of injection should be for maximum efficacy and minimal side effects.

Results of a trial by Brisinda et al (77) suggested that botulinum toxin should be considered to be first-line therapy for anal fissure. In this trial, 50 patients were randomly assigned to either 20 U of botulinum toxin into the IAS or 0.2% GTN paste for six weeks. Healing was found in 96% of patients treated with injection after two months, significantly superior to the 60% healing observed in those using the paste. All nine patients who had failed to heal with GTN treatment healed when retreated with botulinum toxin, suggesting that botulinum toxin, even if not considered first-line therapy, may be useful for refractory fissures. Lysy et al (78) support this suggestion, having shown, in patients with fissures failing to heal with ISDN as first-line therapy, that second-line treatment with botulinum toxin produces good healing rates. Botulinum toxin is even more effective if combined with further ISDN.

The reasons for the apparent superior efficacy of botu-
linum toxin over GTN are not known. As a single injection,
the use of botulinum toxin circumvents any issues of patient compliance. Furthermore, although botulinum toxin's effects last only approximately three or four months, being reversed by the growth of new axon terminals (79), marked short term tachyphylaxis is not encountered in the

same manner as seen with GTN. It will be many years
before it is evident whether there are any long term seque-
lae of botulinum toxin use.

Botulinum toxin has also been injected into the external anal sphincter for the treatment of anismus (80,81), although presumably it has little or no action on the IAS when used in this way.

Calcium channel blockers
Calcium is important to both the maintenance of IAS myo-

genic tone and the response of the IAS to agonists (82).
Calcium channel blockers have been shown to reduce the

mean anal resting pressure as oral (83), sublingual (84) and topical (85) preparations.

In a small, unrandomized study, 15 patients with chronic anal fissure were prescribed oral nifedipine retard 20 mg twice daily, which was shown to reduce the mean anal resting pressure by 36%. After eight weeks, fissure healing was seen in nine patients (60%), and a further three patients (20%) were asymptomatic (86).

In a prospective, randomized, double-blind trial, Antropoli et al (87) compared topical 0.2% nifedipine gel with 1% lidocaine/1% hydrocortisone in the treatment of acute anal fissure. Two hundred eighty-three patients were randomly assigned and treated for 21 days; all patients also received laxatives and an anal dilator. Mean anal resting pressures fell by 30% in the group that received nifedipine; squeeze pressure was also reduced by 17%. Corresponding parameters in the lidocaine/hydrocortisone group were not reduced significantly. Fissure healing was seen in 95% and 50% of patients, respectively. The authors did not observe any side effects. Topical diltiazem has also been employed in uncontrolled studies. A recent report of 71 patients, treated with 2% diltiazem ointment for a median of nine weeks, showed healing in 75% of patients (88). At longer term follow-up (median 32 weeks), approximately one-third of patients had recurrent symptoms, and half of these had clinical evidence of fissure relapse.

Calcium channel blockers have also been examined for
acute, thrombosed, external hemorrhoids in a prospective, randomized, open-label study (89). Ninety patients were randomly assigned to receive either 0.3% nifedipine and 1.5% lidocaine, or 1.5% lidocaine alone. Total relief (defined as absence of pain and swelling) was observed in 92% of the group that received nifedipine group compared with 46% of controls after 14 days of therapy.

Bethanechol paste
Topical 0.1% bethanechol was shown to reduce maximum anal resting pressure by a mean of 24% in 10 normal volun-

teer students, without side effects—an effect that lasted 3 to

5 h (85). In a small, open-label study, healing was observed in 10 of 15 patients with chronic anal fissure treated with 0.1% bethanechol applied three times daily for eight weeks. There were also significant reductions in resting pressures and pain scores, without side effects (90). Randomized, double-blind, placebo controlled studies of this agent are awaited.

Properties of the internal anal sphincter
Adrenoceptor modulators
Pitt et al (91) studied the effects of a single 20 mg dose of oral indoramin, an alpha1-adrenoceptor blocker, in six healthy patients and seven patients with chronic anal fissure. They observed a fall in the mean anal resting pressure of 40% in the healthy subjects, and a fall of 36% after 1 h in those with fissure – an effect that was sustained for 3 h. However, a subsequent randomized, placebo controlled trial examining the use of this agent in patients with anal fissure was abandoned early due to a lack of healing in the treatment arm. Only one of 14 patients in the treatment arm was healed after six weeks of therapy, and the fissure recurred in this patient within three months (92).

There is both in vivo (93) and in vitro (94) evidence to suggest that beta-receptors are upregulated in patients with anal fissure compared with controls. Beta-agonists have been shown to shorten the pain associated with proctalgia fugax (95), and have been shown to reduce the maximum anal resting pressure in both normal control subjects and patients with fissure (96). It is not clear whether the beta-agonists will prove to be an effective treatment for fissure.

AGENT TO INCREASE IAS TONE
In many patients with incontinence, a low anal resting pressure is observed on manometry. The IAS may be structurally intact or show anatomical disruption. In either case, surgery to correct isolated IAS problems has met with little success (97-99). There have been attempts to augment IAS function pharmacologically in this group.

Phenylephrine
In a study of 12 normal volunteers, an 8% rise in the maximum resting pressure was observed after treatment with 5% phenylephrine, but a more impressive (and significant) 33% rise was observed after application of a 10% paste. This effect lasted for a median of 7 h and was not associated with side effects or a change in cardiovascular parameters (100).

A double-blind, random-order, placebo controlled, crossover trial examining the use of 10% phenylephrine gel to treat 12 patients with incontinence after ileoanal pouch construction was performed at St Mark’s Hospital, London, United Kingdom (101). Six patients who received phenylephrine improved subjectively, compared with one patient who received placebo. Four patients had complete cessation of incontinence on the active treatment. Incontinence scores and maximum anal resting pressures were both significantly improved in the treatment group compared with those in the placebo group.

Less encouraging results were seen with 10% phenylephrine gel in a similarly designed study of incontinent patients with ultrasonographically normal sphincters (102). Thirty-six patients (mean age 58 years) were recruited. The results showed no significant improvement in incontinence score, maximum anal resting pressures, or anodermal blood flow. Three patients also suffered a local dermatitis due to the paste. Six patients who received active treatment and two who received placebo, however, reported more than 75% subjective improvement. Only a minority of patients with incontinence may be suitable for this therapy, and future work should seek to identify the characteristics of this group. Furthermore, the IAS from incontinent patients is known to be less responsive in vitro to both noradrenaline and electric field stimulation (103). Higher doses than those established in normal control subjects may be necessary for this group of patients.

This issue was addressed in a subsequent study of 10 patients, also with predominantly passive incontinence and structurally normal anal sphincters (104). Phenylephrine gel was applied in a double-blind manner at concentrations of 0%, 10%, 20%, 30% and 40%, on separate days. All concentrations increased the maximum anal resting pressure relative to placebo, although the difference was significant only for the 30% and 40% concentrations; this effect was sustained for at least 2 h. Effects on incontinence were not reported.

Loperamide
Loperamide has long been one of the mainstays of treatment for fecal incontinence (105). Its effects may not solely be to reduce the water content of the stool. It may also decrease the sensitivity of the rectoanal inhibitory reflex (106) and increase the tone of the anal sphincter (107), although this effect is probably not quantitatively important in vivo.

AGENT TO DECREASE IAS TONE
INTERMITTENTLY AND APPROPRIATELY
Defecatory problems may be attributable to many different causes. However, a small number are attributable to disordered function of the IAS. One example is megarectum. In patients with megarectum, the resting anal canal pressure may be normal, but the degree of relaxation of the IAS in response to a given volume of rectal distension is abnormal. The rectoanal inhibitory reflex is present but requires very large rectal distention volumes in order to be elicited (108).

Phosphodiesterase (PDE) inhibitors have recently been shown to mediate relaxation of the IAS in vitro (109). PDE inhibitors prevent the breakdown of intracellular cAMP and cGMP. Both cAMP and cGMP cause relaxation of the IAS (110). Eleven families of PDEs have been identified to date (111), many with specific inhibitors.

Sildenafil, a PDE-5 inhibitor, has recently been identified as a powerful drug for the treatment of impotence. One of its attractive features is that it has few effects on intracavernosal pressure in the absence of sexual arousal and penile nerve stimulation (112). Its efficacy comes from its ability to augment the vascular smooth muscle relaxation secondary to nitric oxide nerve recruitment. Both the vascular smooth muscle underlying erection and the IAS use the nitric oxide/cGMP/PDE-5 pathway. Although speculative, sildenafil might prove to be useful for augmenting the intermittent and appropriate IAS relaxation. It is not known whether such pharmacological interventions would be widely applicable to the spectrum of problems of disordered...
dejection, although sildenafil has proved to be efficacious in the treatment of impotence secondary to a range of pathologies.

**CONCLUSIONS**
The use of pharmacological agents to manipulate IAS function is in its infancy. Most research into agents to lower IAS pressure has concentrated on the treatment of anal fissure. There has been very little investigation of other conditions that might be ameliorated, including hemorrhoidal disease. By contrast, agents to increase IAS tone have been targeted at incontinent patients, but early results have shown that only a proportion of such patients benefit. Patients with incontinence are a heterogeneous group, and IAS dysfunction is rarely the sole cause of dysfunction.

In the short term, science has benefited from this explosion of interest into the IAS, as the drive for new therapies spawns basic research into the physiology and pharmacology of this tissue. Surgeons and physicians, although not universally convinced of a long term future for pharmacological intervention, have received a timely reminder of the risks to continence inherent in surgery to the anorectum. The long term legacy of a pharmacological approach to benign anorectal disease remains uncertain.

**REFERENCES**

Jones et al
53. Carapeti EA, Kamm MA, McDonald PJ, Chadwick SJD, Melville D, Phillips RKS. Randomised controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate. Gut 1999;44:727-30.

Properties of the internal anal sphincter